MedPath

Safety and Performance Study of the Nyxoah SAT System for Treating OSA

Not Applicable
Terminated
Conditions
Obstructive Sleep Apnea
Interventions
Device: Nyxoah SAT system
Registration Number
NCT02312479
Lead Sponsor
Nyxoah S.A.
Brief Summary

A prospective open-label, single treatment study to assess the safety and the performance of the Nyxoah SAT system for the treatment of Obstructive Sleep Apnea

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
6
Inclusion Criteria
  • Diagnosed with moderate to severe Obstructive Sleep Apnea
  • Have failed or have not tolerated CPAP treatment
  • Willing and capable of providing informed consent
  • Willing and capable of returning to all follow-up visits and sleep studies, including evaluation procedures and filling out questionnaires
Exclusion Criteria
  • BMI limits
  • Subjects with complete concentric collapse at the soft palate level per endoscopy

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Nyxoah SAT therapyNyxoah SAT system-
Primary Outcome Measures
NameTimeMethod
Mean change of AHI (Apnea-Hypopnea Index) measured by in-lab polysomnography (PSG) from baseline measurement to 6-months post-implantation6-months post-implantation
Incidence of serious device related adverse events6-months post-implantation
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

Antwerp University Hospital

🇧🇪

Edegem, Belgium

Universitäts-HNO-Klinik Mannheim

🇩🇪

Mannheim, Germany

© Copyright 2025. All Rights Reserved by MedPath